Webinar
Peptides explained: You asked. Clinical experts answer.
There’s a lot of confusion in the peptides space. OpenLoop’s clinical experts answer the burning questions operators like you are asking about peptides: what the research does and doesn’t show, what the new HHS interim policy means for your business, and why clinical judgment should stay at the center of your program.
November 19, 2026 | 11:15 A.M. – 12:00 P.M. CT
-
Dr. Mohit Joshipura, MD, Dipl. ABOM, CMO
-
Dr. Melissa Loseke, DO, Sr. Director, Longevity and New Programs
What you’ll learn
-
01
Cut through the confusion
A brief peptide background, what the research does and doesn’t show, and what terms like “FDA-approved,” “503A compounding,” and “research use only (RUO)” actually mean.
-
02
Know where the new HHS interim policy stands
What the interim enforcement discretion policy does and doesn’t say, and what is still unknown or subject to change.
-
03
See why clinicians should lead
Why a clinician-led, prescription pathway is the responsible approach to a peptide program, and how it differs from research-use-only products.
-
04
Keep clinical judgment at the center
Why clinicians need real freedom to say no, and why that makes a program stronger, not slower.
-
05
Build in ongoing care and safety
Patient evaluation, dosing control, side effects, and monitoring, and what each means for how you set up your program.
Submit your burning
peptide question
Tell us what questions you have, and we’ll work to incorporate it into our webinar! With so much confusion in the space, our goal is to create clarity about the landscape so you can approach peptides with more confidence.
Meet the experts
-
Mohit Joshipura, MD, Dipl. ABOM
Chief Medical Officer, OpenLoop
Mohit Joshipura, MD, is the Chief Medical Officer at OpenLoop, where he sets the company’s clinical strategy and leads the teams that deliver clinical quality, training, and performance across the platform. Dr. Joshipura is a multistate-licensed physician, dual board-certified in Internal Medicine and Obesity Medicine, and has deep experience designing and operationalizing digital health solutions across the value-based care, B2B2C, and DTC landscapes. Having served as a senior clinical leader at mid and late-stage startups, he has contributed to the development of multiple virtual and hybrid clinical protocols, spanning 50+ conditions and both asynchronous and synchronous modalities, and has led innovative program design initiatives. His telehealth experience spans clients ranging from early-stage startups and established consumer health brands to life science and pharmaceutical companies, top three health insurers, and Fortune 500 multinationals.
-
Melissa Loseke, DO
Sr. Director, Longevity and New Programs, OpenLoop
Dr. Melissa Loseke, D.O., is a multistate-licensed physician and longevity medicine leader with nearly two decades of experience in regenerative, functional, and integrative care. Her clinical focus spans hormone optimization, peptides, medical weight loss, and aesthetics, and she is passionate about expanding access to personalized, precision high-quality care. A senior clinical leader, Dr. Loseke has served as Chief Medical Officer and Director of Clinical Operations for multiple healthcare organizations, where she developed clinical protocols, trained physicians and advanced practice providers, and partnered cross-functionally with operations, product, and business teams to support growth.